Camparison of tab bilastine vs tab levovetrizine in treatment of urticaria
Phase 3
- Conditions
- Health Condition 1: L509- Urticaria, unspecified
- Registration Number
- CTRI/2020/12/030117
- Lead Sponsor
- Dr shreya somani
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
Inclusion Criteria
Patients of urticaria aged 15-80 years willimg to give consent will be imcluded in study
Exclusion Criteria
Patients with urticarial vsculitis, senile pruritus, drug induced urticaria will be excluded. Patients with hypersensitivity to drug will be excluded. Pregnant and lactating females will be excluded
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method